Insuman Rapid solution for injections 100 IU/ml. cartridge 3 ml. №5

Description

Insuman Composition
active substance: human insulin;

1 ml of solution contains 100 IU of human insulin (equivalent to 3,571 mg of human insulin);

Excipients: m-cresol, concentrated hydrochloric acid, sodium hydroxide, sodium phosphate dihydrate, glycerin (85%), water for injections.

Insuman Dosage form

Solution for injection.

Basic physical and chemical properties: transparent, colorless or almost colorless solution.

Insuman Pharmacotherapeutic group

Antidiabetic drugs. Insulins and short-acting analogues for injectable use. ATX code A10A B01.

Pharmacological properties

Insuman Rapid® is a solution of neutral insulin (simple insulin).

Mechanism of action.

Insulin:

lowers blood sugar and promotes anabolic effects, as well as reduces catabolic effects;
enhances intracellular glucose transport, as well as the formation of glycogen in muscles and liver, increases the use of pyruvate. Insulin inhibits glycogenolysis and gluconeogenesis;
enhances lipogenesis in the liver and adipose tissue and inhibits lipolysis;
improves intracellular amino acid intake and enhances protein synthesis,
enhances intracellular potassium intake.
Pharmacodynamics.

Insuman Rapid® is a fast-acting, short-acting insulin. It begins 30 minutes after subcutaneous injection, reaches a maximum in 1-4 hours and lasts for 7-9 hours.

Pharmacokinetics.

In healthy volunteers, the half-life of serum insulin is about 4-6 minutes. This period is longer in patients with severe renal insufficiency. However, it should be noted that the pharmacokinetics of insulin do not reflect its metabolic action.

Indications
Diabetes that requires insulin therapy. Insuman Rapid® can also be used to treat hyperglycaemic coma and ketoacidosis or to stabilize patients with diabetes before, during and after surgery.

Contraindications
Hypersensitivity to the active substance or to any of the excipients included in the drug. Hypoglycemia.

Special security measures

Patients with hypersensitivity to Insuman Rapid®, for whom there is no other better tolerated drug, should continue treatment only under close medical supervision and, if necessary, with concomitant use of anti-allergic drugs.

If blood sugar control is inadequate or there is a tendency to develop hypo- or hyperglycaemia, the patient should be monitored for adherence to the prescribed treatment regimen, injection technique and injection site, and other important factors should be assessed before adjusting the dose.